Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C
Quarter
BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
NESS ZIONA, Israel–(BUSINESS WIRE)–Mar 31, 2021– BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”),
XpresSpa Group Provides Business Update and Announces Fourth Quarter 2020 Financial Results
Eleven XpresCheck Wellness Centers Currently Operating with Two Additional Locations to Open Soon Positioned to
AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for
Frequency Therapeutics Supplies Enterprise Updates and Reports Fourth Quarter and Full Year 2020 Fiscal Results
WOBURN, Mass.–(Enterprise WIRE)–Mar 29, 2021– Frequency Therapeutics, Inc. (Nasdaq: FREQ), a medical-stage biotechnology organization concentrated
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter
Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau® Pro
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
– Advanced ALG-010133 and ALG-000184 into the clinic – both expected to generate safety and
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported
Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update
Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including
PLAYSTUDIOS, Inc. Announces Preliminary Fourth Quarter and Full Year 2020 Results Along With Recent Business Highlights
– Fourth Quarter Revenue of $64.0 million and Full Year 2020 Revenue of $269.9 million,
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and …
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the
Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises Initiation
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing
22nd Century Team Reports Small business Highlights and Economic Success for the Fourth Quarter and … | Income
Hemp/Hashish Franchise Highlights and Recent Essential Gatherings Given that reporting 3rd quarter earnings, 22nd Century